Jason S. Miyares
Attorney General of Virginia

Image of the Virginia AG Seal

Commonwealth of Virginia
Office of the Attorney General

Jason S. Miyares
Attorney General


202 North 9th Street
Richmond, Virginia 23219
FAX 804-786-1991
Virginia Relay Service

For media inquiries only, contact:  
Victoria LaCivita
(804) 588-2021 
This email address is being protected from spambots. You need JavaScript enabled to view it.

Attorney General Miyares Announces $2.37 Billion National Agreement With Former Opioid Maker Allergan

~Virginia will receive at least $40 million, following the expected $70 million from the Teva Settlement ~ 

Richmond, VA – Virginia Attorney General Miyares and a bipartisan group of Attorneys General today announced an agreement in principle to address the opioid crisis for the second time this week. The proposed settlement on important financial terms would require former opioid maker Allergan to pay up to $2.37 billion to participating states and local governments.  


"The opioid epidemic is widespread and aggressive. Settlements like these will help create policies and programs designed to reduce, prevent, and treat opioid addiction. We continue to make it a priority to hold manufacturers responsible for their part in the opioid crisis, while ensuring victims of this epidemic receive the help they need,” said Attorney General Miyares.



If finalized, the Allergan settlement, together with the Teva Pharmaceuticals settlement announced Tuesday, would provide as much as $6.6 billion nationwide, including for abatement of the crisis. AbbVie, which acquired Allergan in 2020, disclosed the agreement in its earnings announcement Friday. Altogether, Virginia can expect to receive over $100 million if the settlements are finalized.  


Both settlements remain contingent on resolution of key issues, including details regarding the settlement structure, which is expected to build on the framework developed in prior nationwide opioid settlements. The parties are also negotiating terms requiring business practice changes and transparency. 


Ireland-based Allergan formerly made Norco- and Kadian-branded and generic opioids. The company sold its generics portfolio, including opioid products, to Teva in 2016. Teva and the Attorneys General announced Tuesday that they had reached an agreement in principle to provide up to $4.25 billion to address its part in the opioid crisis. The Teva agreement in principle is contingent, in part, on Allergan reaching its own settlement with the states. 


The coalition of states alleged that Allergan: 

  • Deceptively marketed opioids by downplaying the risk of addiction, overstating their benefits, and encouraging doctors to treat patients showing signs of addiction by prescribing them more opioids; and
  • Failed to maintain effective controls to prevent diversion of opioids.

The $2.37 billion figure includes money that Allergan has already agreed to pay under settlements with individual states.


The negotiations are being led by California, Iowa, Illinois, Maryland, Massachusetts, New York, North Carolina, Pennsylvania, Tennessee, Texas, Vermont, Virginia, and Wisconsin. While New York was among the 13 states integral to negotiating this settlement, New York settled separately with Allergan in December 2021 as a part of its trial.